The New NCI Precision Medicine Trials.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
received:
27
03
2023
revised:
06
06
2023
accepted:
20
07
2023
medline:
4
12
2023
pubmed:
2
8
2023
entrez:
2
8
2023
Statut:
ppublish
Résumé
Basket, umbrella, and platform trial designs (master protocols) have emerged over the last decade to study precision medicine approaches in oncology. First-generation trials like NCI-MATCH (Molecular Analysis for Therapy Choice) have proven the principle that studying targeted therapies on a large scale is feasible both from the laboratory and clinical perspectives. However, single-agent targeted therapies have shown limited ability to control metastatic disease, despite careful matching of drug to target. As such, newer approaches employing combinations of targeted therapy, or targeted therapy with standard therapies, need to be considered. The NCI has recently embarked on three second-generation precision medicine trials to address this need: ComboMATCH, iMATCH, and myeloMATCH. The design of these trials and necessary infrastructure are discussed in the following perspective.
Identifiants
pubmed: 37531248
pii: 728183
doi: 10.1158/1078-0432.CCR-23-0917
pmc: PMC10690084
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4728-4732Subventions
Organisme : NCI NIH HHS
ID : U10 CA180819
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180888
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233329
Pays : United States
Informations de copyright
©2023 The Authors; Published by the American Association for Cancer Research.
Références
J Natl Cancer Inst. 2020 Oct 1;112(10):1021-1029
pubmed: 31922567
Nat Med. 2022 Apr;28(4):658-665
pubmed: 35440717
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
Ann Oncol. 2022 Feb;33(2):143-157
pubmed: 34808340
Clin Cancer Res. 2023 Apr 14;29(8):1412-1422
pubmed: 36662819
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
J Clin Oncol. 2020 Nov 20;38(33):3883-3894
pubmed: 33048619